Hieromnimon, Hanna M.
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Article History
First Online: 28 June 2022
Competing interests
: A.T.P. serves on advisory boards for Ayala, Elevar and Prelude Therapeutics; has consulting roles for Abbvie; and reports research funding from Abbvie and Kura Oncology. A.T.P. reports effort support via grants from NIH/NCI U01-CA243075, NIH/NIDCR R56-DE030958, NIH/NCI R25-CA240134, EU Horizon 2021-SC1-BHC, SU2C (Stand Up to Cancer) Fanconi Anemia Research Fund – Farrah Fawcett Foundation Head and Neck Cancer Research Team Grant during the conduct of the study. This has been funded in whole or in part with Federal funding by the NCI-DOE Collaboration established by the US Department of Energy (DOE) and the National Cancer Institute (NCI) of the National Institutes of Health (NIH), Cancer Moonshot Task Order no. 75N91019F00134 and under Frederick National Laboratory for Cancer Research Contract 75N91019D00024. This work was performed under the auspices of the US DOE by Argonne National Laboratory under Contract DE-AC02-06-CH11357.